Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Genes (Basel) ; 13(11)2022 11 15.
Artigo em Inglês | MEDLINE | ID: mdl-36421794

RESUMO

We report on a cohort of 204 children referred between January 2017 and January 2022 to the German Center for Ectodermal Dysplasias, Erlangen. The most frequent reasons for referral were tooth malformations and lack of multiple teeth leading to the suspicion of an ectodermal dysplasia. Many patients also suffered from being unable to perspire. Nail abnormalities, in contrast, represented a much rarer finding, albeit the impact on some individuals was large. As ectodermal dysplasias are congenital genetic conditions affecting the development and/or homeostasis of two or more ectodermal derivatives, including hair, teeth, nails, and certain glands, we analyzed congenital nail disorders detected in these patients. Dystrophic or otherwise abnormal nails were evident in 17 of 18 subjects with pathogenic WNT10A or GJB6 variants but in none of 161 children with EDA variants underlying X-linked hypohidrotic ectodermal dysplasia. However, 2 of 17 children who carry mutations in EDAR or EDARADD, two other genes involved in the ectodysplasin A signaling pathway, showed nail abnormalities, such as brittle or hypoplastic nails. TP63 variants were regularly associated with nail disorders. In one girl, anonychia congenita caused by a compound heterozygous variant of the R-spondin-4 gene (RSPO4) was diagnosed. Thus, nail dysplasia is rarer among patients with ectodermal dysplasia than commonly thought.


Assuntos
Displasia Ectodérmica , Deformidades Congênitas dos Membros , Unhas Malformadas , Criança , Feminino , Humanos , Unhas , Displasia Ectodérmica/genética , Unhas Malformadas/genética , Ectoderma
3.
Dtsch Arztebl Int ; 114(5): 72, 2017 02 03.
Artigo em Inglês | MEDLINE | ID: mdl-28241920
4.
Reprod Sci ; 22(6): 735-42, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25415335

RESUMO

The soluble fms-like tyrosine kinase 1 (sFlt-1), known to be increased in the serum of preeclamptic patients, is a relevant factor in causing maternal symptoms like hypertension and proteinuria. In this study, we aimed to reveal whether hypoxia is a cause of increased sFlt-1 levels and inflammation markers in vivo and whether these symptoms can be attenuated by interleukin 6 (IL-6) depletion. For this purpose, pregnant wild-type (wt) mice or IL-6(-/-) mice on embryonic day 16 were placed under either normoxic (20.9% oxygen) or hypoxic (6% oxygen) conditions for 6 hours. This led to a rise of sFlt-1 levels in maternal serum, independent of the IL-6 status of the dam. Increased maternal sFlt-1 serum levels were, however, not due to an increase in sFlt-1 messenger RNA levels in the placenta. Moreover, there was no increase in inflammatory markers in neither wt mice nor IL-6(-/-) mice. This suggests that hypoxia alone does not contribute to the induction of an inflammatory placenta. Also, the hypoxia-induced rise in sFlt-1 levels seems not to be mediated by IL-6 in vivo.


Assuntos
Hipóxia/enzimologia , Inflamação/enzimologia , Interleucina-6/deficiência , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/sangue , Animais , Modelos Animais de Doenças , Feminino , Idade Gestacional , Hipóxia/sangue , Hipóxia/genética , Hipóxia/imunologia , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Inflamação/sangue , Inflamação/genética , Inflamação/imunologia , Interleucina-6/genética , Camundongos Endogâmicos C57BL , Camundongos Knockout , Placenta/imunologia , Placenta/metabolismo , Gravidez , Regulação para Cima , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/genética
5.
Pediatr Cardiol ; 33(4): 586-90, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22307401

RESUMO

The patent ductus arteriosus (PDA) is associated with various complications of prematurity. Cyclooxygenase-inhibitors are the first-line intervention for closure of the PDA. However, the rates of PDA closure still are unsatisfactory. Therefore, an individual trial was performed by changing the strategy for treating neonates with ibuprofen to induce the closure of PDA. In a retrospective study, patients receiving 20, 10, and 10 mg/kg bodyweight ibuprofen (group 1) were compared by chart review with those receiving 10, 5, 5 mg/kg (group 2). The rate of PDA closure, the incidence of side effects related to the use of ibuprofen, and the need for surgical intervention for closure of the PDA were analyzed. A higher rate of closure after three doses in group 1 could be observed (60.9 vs 52.6%; p = 0.75), which was not significant but indicated a clear positive trend. If closure of the PDA was unsuccessful, intravenous ibuprofen was continued for an additional 2 days. After 5 days, 91.3% of PDA in group 1 was closed compared with 68.4% PDA in group 2. In summary, only 8.7% of the group 1 neonates needed surgical closure of PDA after insufficient medicamentous closure compared with 31.6% in group 2 (p = 0.25). Although not statistically significant, a clear positive trend for using the higher-dose medication can be seen. More work dealing with the limitations of a retrospective study must be done. Based on the data from this study, high-dose ibuprofen seems able to increase the rate of effective medicamentous PDA closure without any further unwanted side effects.


Assuntos
Inibidores de Ciclo-Oxigenase/administração & dosagem , Permeabilidade do Canal Arterial/tratamento farmacológico , Ibuprofeno/administração & dosagem , Peso Corporal , Procedimentos Cirúrgicos Cardíacos/estatística & dados numéricos , Relação Dose-Resposta a Droga , Permeabilidade do Canal Arterial/diagnóstico , Permeabilidade do Canal Arterial/cirurgia , Ecocardiografia , Seguimentos , Humanos , Recém-Nascido , Injeções Intravenosas , Estudos Retrospectivos , Índice de Gravidade de Doença , Resultado do Tratamento
6.
Regul Pept ; 167(1): 156-62, 2011 Feb 25.
Artigo em Inglês | MEDLINE | ID: mdl-21237211

RESUMO

OBJECTIVE: Leptin and its receptor (Ob-R) are co-expressed in human placenta suggesting auto- and paracrine mechanisms of the hormone. So far it is unclear, how changes in the placental environment affect Ob-R expression. Hence, the main purpose of the study was to investigate leptin receptor expression and regulation under hypoxic conditions. The influences of hypoxia and leptin on signal transduction and cell proliferation in chorioncarcinoma cell lines as well as primary villous trophoblasts were determined. RESULTS: We found a time-dependent induction of leptin receptor mRNA and protein in placental cells under hypoxic conditions. In contrast, soluble leptin receptor expression did not change under oxygen deprivation. Leptin treatment neither activated the p42/p44 nor the STAT3 pathway in placental cells, being independent of hypoxic or normoxic conditions. Furthermore, leptin added to the culture medium in high concentrations was unable to interfere with the rate of proliferation. CONCLUSION: Our data demonstrate that hypoxia leads to an increase of Ob-R expression in placental cells. Interestingly, leptin-dependent signal transduction and proliferation remained unaffected. A possible role of the soluble leptin receptor in modulating free leptin levels will be discussed.


Assuntos
Coriocarcinoma/metabolismo , Hipóxia/metabolismo , Leptina/metabolismo , Leptina/farmacologia , Receptores para Leptina/metabolismo , Neoplasias Uterinas/metabolismo , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Coriocarcinoma/genética , Coriocarcinoma/patologia , Vilosidades Coriônicas , Feminino , Expressão Gênica/efeitos dos fármacos , Humanos , Leptina/genética , Proteína Quinase 1 Ativada por Mitógeno/genética , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno/genética , Proteína Quinase 3 Ativada por Mitógeno/metabolismo , Oxigênio/metabolismo , Placenta/citologia , Placenta/metabolismo , Gravidez , RNA Mensageiro/análise , Receptores para Leptina/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fator de Transcrição STAT3/genética , Fator de Transcrição STAT3/metabolismo , Transdução de Sinais/efeitos dos fármacos , Trofoblastos/citologia , Trofoblastos/metabolismo , Regulação para Cima/efeitos dos fármacos , Neoplasias Uterinas/genética , Neoplasias Uterinas/patologia
7.
Regul Pept ; 153(1-3): 25-9, 2009 Feb 25.
Artigo em Inglês | MEDLINE | ID: mdl-19100295

RESUMO

OBJECTIVE: Hypoxia and insulin are known key players in the activation leptin transcription and translation in vivo and in vitro. These insulin- and hypoxia-dependent effects are leptin transcription are mediated via independent elements on the leptin-promotor, even more coincubation of the two stimuli in vitro results in a supraadditive effect on leptin transcription. The aim of this study was to examine whether hyperinsulinemia is able to interfere with the hypoxia-driven expression of leptin in adipose and extra-adipose tissue in vivo. RESEARCH METHODS AND PROCEDURES: We used the KK/HlJ mouse strain as a model for hyperinsulinemia and C57BL/6J mice as control. These two groups were exposed to hypoxia for 12 h. Serum levels of insulin and leptin were analyzed by ELISA, mRNA expression of leptin was measured via real-time PCR. RESULTS: In the hyperinsulinemic KK/HlJ mice, hypoxia was not able to further increase the amount of leptin in serum. Instead, a significant decrease of insulin levels was detected, while serum leptin and insulin levels increased in C57BL/6J. Analysis of leptin mRNA expression in subcutaneous fat, mesenteric fat and kidney revealed that hypoxia induces leptin transcription in kidneys of C57/BL6 but not in hyperinsulinemic animals. In contrast, leptin expression in adipose tissue was not increased during hypoxia. DISCUSSION: We conclude that leptin regulation during hypoxia in vivo depends at least in part on the modulating role of insulin. The hypoxia driven induction of insulin expression in C57/BL6 animals may be responsible for the stimulation of leptin transcription. In contrast, already hyperinsulinemic animals showed no induction - neither of insulin nor leptin after short-term hypoxia.


Assuntos
Hiperinsulinismo/metabolismo , Hipóxia/metabolismo , Leptina/metabolismo , Animais , Glicemia/metabolismo , Peso Corporal , Insulina/sangue , Leptina/genética , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Transcrição Gênica
8.
Growth Factors ; 26(6): 355-64, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18951274

RESUMO

Intrauterine growth restriction (IUGR) is a risk factor for the development of hypertension in later life. Insulin-like growth factor I and growth hormone (GH) have the potential to improve metabolic syndrome after IUGR in adult animals. The objective of the present study was to examine whether transient GH treatment of pups after weaning can prevent the development of arterial hypertension in adult rats. IUGR was induced in Wistar rats by isocaloric protein restriction in pregnant dams and litter size was reduced to six male neonates after birth. Recombinant human GH was applied by daily subcutaneous injections at a dose of 3 microg/g body weight between days 24 and 60 of life. Control animals received vehicle treatment (VEH) only. Birth weight was significantly lower in low protein (LP) animals than in normal protein (NP) animals (5.1 +/- 0.3 g vs. 5.9 +/- 0.7 g, p < 0.05). Until weaning at day 23, LP animals reached similar body length, but had reduced body weight compared to NP animals. Intraarterially measured mean arterial blood pressure at day 120 was elevated in LP-VEH compared to NP-VEH animals (113 +/- 6 mmHg vs. 101 +/- 6 mmHg, p < 0.01). However, transient GH-treatment did not prevent arterial hypertension in LP animals (112 +/- 5 mmHg). Our data suggest that GH treatment between days 24 and 60 of life does not or at least not permanently reprogram blood pressure elevation after IUGR.


Assuntos
Retardo do Crescimento Fetal/terapia , Hormônio do Crescimento Humano/uso terapêutico , Hipertensão/prevenção & controle , Proteínas Recombinantes/uso terapêutico , Animais , Animais Recém-Nascidos/crescimento & desenvolvimento , Animais Recém-Nascidos/metabolismo , Peso ao Nascer , Pressão Sanguínea , Peso Corporal , Dieta com Restrição de Proteínas , Feminino , Retardo do Crescimento Fetal/etiologia , Humanos , Hipertensão/fisiopatologia , Tamanho da Ninhada de Vivíparos , Masculino , Gravidez , Ratos , Ratos Wistar , Resultado do Tratamento
9.
Clin Endocrinol (Oxf) ; 67(2): 304-9, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17555509

RESUMO

OBJECTIVE: Low birthweight is a risk factor for metabolic and cardiovascular disorders in later adult life. Changes in the activity of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) and the consequent disequilibrium between cortisol (F) and cortisone (E) are thought to be a key mechanism for these effects. We investigated whether prenatal programming leads to alterations in F/E ratios on a systemic level. DESIGN, PATIENTS AND METHODS: In a cross-sectional, retrospective study we analysed sera of 132 children born small for gestational age (SGA) (aged 2-13 years) with persistent short stature [< -2 standard deviation score (SDS)] and of 25 children born appropriate for gestational age (AGA) (aged 4-11 years) with normal body height. Thirty-one per cent of the SGA and 44% of the AGA children were born preterm. Serum E and F concentrations were measured using tandem mass spectrometry. To exclude species-specific effects, we studied the 11beta-HSD system by measuring the ratio of corticosterone (B) to dehydrocorticosterone (11OH-B) in rats that were born SGA after protein restriction of the female dams during pregnancy. RESULTS: F, E and the F/E ratio in serum did not differ in these children when comparing SGA to children who were born AGA and had normal height. The concentrations were independent of weight and length SDS at birth as well as gestational age. In rats born SGA, the B/11OH-B ratio was not different to that in normal control animals at 6, 11 and 15 weeks of life. CONCLUSION: We found no alterations in systemic cortisol-cortisone conversion either in short children born SGA or in SGA rats. However, local modifications of the 11beta-HSD system may be possible.


Assuntos
Cortisona/sangue , Transtornos do Crescimento/sangue , Hidrocortisona/sangue , Recém-Nascido Pequeno para a Idade Gestacional/sangue , Adolescente , Animais , Estudos de Casos e Controles , Criança , Pré-Escolar , Estudos Transversais , Feminino , Desenvolvimento Fetal , Humanos , Recém-Nascido , Recém-Nascido Prematuro/sangue , Modelos Lineares , Masculino , Gravidez , Ratos
10.
Apoptosis ; 12(1): 37-43, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17080327

RESUMO

Fusiogenic glycoprotein syncytin-1, expressed in human placenta, is a promising candidate for acquiring a basic knowledge of placental syncytialization. However, its cellular mode of action is unidentified. We investigated whether syncytin-1 may exert influence on apoptotic processes. Therefore, we incubated CHO cells after stable transfection with syncytin-1 (CHO-52) in the presence or absence of staurosporine (STS), a kinase inhibitor well characterized to induce apoptosis. When testing the phenotype of CHO-52 cells, we could demonstrate that the induction of apoptosis by STS was delayed over a period of up to 24 h. Furthermore, the cell death rate was decreased by approx 75% following transfection of syncytin-1 in CHO-52 compared to mock-treated cells. In detail, after 18h of incubation with 500 nM STS, 64 +/- 2% of CHO-52 cells were viable compared to 16 +/- 1% of CHO-mocks, after 24 h 43 +/- 3% vs 5 +/- 2%, respectively. CHO-52 cells exhibited a lower expression of active caspase 3 and anti-apoptotic Bcl-2 was found to be increased in CHO-52 cells at baseline and following STS treatment. Our study provides first evidence that syncytin-1 serves anti-apoptotic function under certain conditions. A lessened activation of caspase 3 and an increased expression of Bcl-2 are possible mechanisms.


Assuntos
Apoptose/efeitos dos fármacos , Apoptose/fisiologia , Produtos do Gene env/fisiologia , Proteínas da Gravidez/fisiologia , Estaurosporina/farmacologia , Animais , Células CHO , Fusão Celular , Cricetinae , Cricetulus , Retrovirus Endógenos/genética , Retrovirus Endógenos/fisiologia , Feminino , Produtos do Gene env/genética , Humanos , Técnicas In Vitro , Microscopia de Fluorescência , Gravidez , Proteínas da Gravidez/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Transfecção
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA